Financings in Brief: Endocare
This article was originally published in The Gray Sheet
Executive SummaryEndocare: Secures two-year, $1.5 mil. borrowing facility through partnerships managed by venture capital firm Technology Funding. Endocare, which has developed the CryoCare cryosurgery system for treatment of prostate cancer, says this facility provides necessary working capital "for aggressively marketing" the CryoCare system. "It also provides a foundation to support long-term development of our third-stage, office-based therapy product for prostate enlargement," the company says...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.